BRCA2 and ovarian cancer: The median of this score was higher for patients with pathogenic germline variants in comparison to patients where no germline variants or a VUS was identified, reflecting that a family history of breast and/or ovarian cancer increases significantly the chance of identifying women with a germline BRCA1/BRCA2 variant.